GlycoVaxyn's technology paves the way for synthesizing bioconjugate material to levels previously unattainable and in a more cost-effective manner.

06.10.09 GlycoVaxyn Appoints Renowned Vaccinologist Dr. Stanley Plotkin to Supervisory Board 05.03.09 GlycoVaxyn Announces its Series B Financing Round

GlycoVaxyn will be presenting at the VACCINE INNOVATION MEETING in Frankfurt, Germany on April 28-29, 2010